Pharma stock engaged in manufacturing, marketing, importing, and exporting a variety of healthcare products, and pharmaceutical dosages in focus upon receiving work order worth Rs. 6.3 Crores to supply antiseptic agents.
Price Action
With a market capitalization of Rs. 62 Crores, the shares of Medicamen Organics Limited were trading at Rs. 52.95 per equity share, up 1.83 percent from its previous day’s close price of Rs. 52.
What Happened
Medicamen Organics Limited has received a new work order for the supply of 7.39 Lakh Units of Povidone Iodine 10% SOL US EXT, FU200 ML, for a consideration of Rs. 6.3 Crores.
Povidone Iodine 10% Solution is widely used in healthcare for its antiseptic properties, and the company is excited to meet the growing demand from customers in this segment. This order is a testament to the company’s ongoing commitment to expanding its market footprint and serving the healthcare sector with high-quality products.
Management Message
Mr. Ashutosh Gupta, Whole-time Director, Medicamen Organics Limited, commented, “We are excited to announce the receipt of this substantial order. It underscores the trust our customers place in us and reinforces our strong position in the market. We are confident that we will be able to fulfill this order within the stipulated timelines and continue to deliver high-quality products to our clients.”
The company will continue to monitor developments related to this order and provide further updates as necessary. This order is expected to contribute significantly to the company’s revenue in the upcoming quarters.
About the Company
Medicamen Organics Limited is a prominent Indian pharmaceutical company engaged in manufacturing, marketing, importing, and exporting a variety of healthcare products, and pharmaceutical dosages including generic doses in the form of tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders.
Financials & Ratios
Its Revenue from operations grew by 47 percent YoY from Rs. 11.32 Crores in H1FY24 to Rs. 16.61 Crores in H2FY25, accompanied by profits of Rs. 1.36 Crores to Rs. 1.51 Crores.
In terms of Return ratios, it has reported a return on equity (ROE) of 19.9 percent and a return on capital employed (ROCE) of 16.6 percent. It has reported a debt-to-equity ratio of 0.47.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
